Pfizer Cash Flow
- Market cap
- ₹17,426 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹2,742.62 – ₹5,142.42
In the year ended FY25, Pfizer generated ₹1,046 crore from operating activities, invested ₹697 crore and paid out ₹261 crore on financing activities. Net cash flow for the year was ₹87.13 crore. Free cash flow was ₹436 crore.
Pfizer cash flow statement
Financial years, newest first. Negative figures are cash outflows.
| Item | FY25 |
|---|---|
| Cash from operating activities | 1,046 |
| Cash from investing activities | -697 |
| Cash from financing activities | -261 |
| Net cash flow | 87.13 |
| Capital expenditure | 610 |
| Free cash flow | 436 |
Source: Company filings, in ₹ crore. Data as of 9 October 2026. How this data is compiled.
Pfizer cash flow — frequently asked questions
What is Pfizer's operating cash flow?
Pfizer's cash flow from operating activities was ₹1,046 crore in the year ended FY25.
What is Pfizer's free cash flow?
Pfizer's free cash flow — operating cash flow minus capital expenditure — was ₹436 crore in FY25, after capital expenditure of ₹610 crore.
How much did Pfizer spend on investing activities?
Net cash used in investing activities was ₹697 crore in FY25. This covers capital expenditure, acquisitions and the purchase or sale of investments.
Same Data For Peers
Trade Pfizer With ATS
Track PFIZER live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.